Pay to Marwadi

Company Profile

NATCO PHARMA LTD.

NSE : NATCOPHARMBSE : 524816ISIN CODE : INE987B01026Industry : Pharmaceuticals & DrugsHouse : Natco
BSE1031.259.2 (+0.9 % )
PREV CLOSE (Rs.) 1022.05
OPEN PRICE (Rs.) 1026.35
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 101659
TODAY'S LOW / HIGH (Rs.)1025.05 1058.95
52 WK LOW / HIGH (Rs.)566.85 1107.85
NSE1027.90 6.75 (+0.66 % )
PREV CLOSE(Rs.) 1021.15
OPEN PRICE (Rs.) 1030.00
BID PRICE (QTY) 1027.90 (165 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 1157262
TODAY'S LOW / HIGH(Rs.) 1024.45 1059.00
52 WK LOW / HIGH (Rs.)565.8 1108.35

Company Profile

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.53
TTM EPS (Rs.) 67.65
P/E Ratio 15.24
Book Value (Rs.) 295.19
Face Value (Rs.) 2
MCap (Rs. in Mn) 184707.05
Price/Earning (TTM) 13.49
Price/Sales (TTM) 5.46
Price/Book (MRQ) 3.49
PAT Margin (%) 26.57
ROCE (%) 16.51
Incorporation Year : 1981

Management Info :

G S Murthy - Chairman V C Nannapaneni - Managing Director

Registered Office :

Address : Natco House,Road No 2,Banjara Hills,
Hyderabad,
Telangana-500034

Phone : 040-23547532

Registrar's Details : Venture Capital & Corporate Investments Ltd
Aurum, Door No 4-50/P-II/57/4F&5F Plot No 57,4th & 5th Floors,Jayabheri Enclave Phase - II, Gachibowli,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
23Apr04-23-2024$NATCO Pharma informs about disclosure NATCO Pharma informs about d
Further to its earlier intimation dated November 2, 2023 about the successful completion of United States Food and Drug Administration’s (USFDA) inspection of the firm’s compliance to Pharmacovigilance requirements with zero observations, NATCO Pharma has informed that the Company is in receipt of the Establishment Inspection Report (EIR) from USFDA concluding the inspection as Closed.

The above information is a part of company’s filings submitted to BSE.
Further to its earlier intimation dated November 2, 2023 about..
18Apr04-18-2024$NATCO Pharma informs about press release NATCO Pharma informs about p

NATCO Pharma has informed that it enclosed the Press Release and disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The above information is a part of company’s filings submitted to BSE.

NATCO Pharma has informed that it enclosed the Press Release an..
09Apr04-09-2024$Natco Pharma gets warning letter from USFDA for Telangana plant Natco Pharma gets warning le

Natco Pharma has received a warning letter from the US health regulator for its Telangana-based manufacturing plant. The US Food and Drug Administration (USFDA) had issued eight observations under Form 483 after inspecting the company's Kothur-based formulation facility. The inspection was conducted by USFDA from October 9 to October 18, 2023. The company does not believe that the warning letter will have an impact on supplies or the existing revenues from this facility. It may cause delay/withholding of pending product approvals from this site. 

The drug firm will respond to the letter within the stipulated timelines and work closely with the USFDA to address the concerns in a holistic and timely manner to ensure sustained compliance. A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations. 

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma has received a warning letter from the US health r..
09Apr04-09-2024$NATCO Pharma informs about updates NATCO Pharma informs about u

NATCO Pharma has informed about update on USFDA inspection at Natco’s manufacturing facility in Kothur, Telangana.

The above information is a part of company’s filings submitted to BSE.

NATCO Pharma has informed about update on USFDA inspection at N..
09Apr04-09-2024$ Update On USFDA Inspection At Natco'S Manufacturing Facility In Kothur, Telangana Update On USFDA Inspection
Update on USFDA inspection at NATCO''s Manufacturing facility in Kothur, Telangana
Update on USFDA inspection at NATCO''s Manufacturing facility i..
Financials More
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit19206371
Gross Profit 2236 7707
Operating Profit 26789302
Net Sales 625323510
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Divi's Lab (BSE)
 4025.35 (4.81%)
M.Cap ( in Cr)
106860.39
Sanofi India (BSE)
 8278.10 (1.76%)
M.Cap ( in Cr)
19064.98
Abbott India (BSE)
 25864.85 (0.54%)
M.Cap ( in Cr)
54961.00
Astrazeneca Pharma I (BSE)
 5415.40 (2.18%)
M.Cap ( in Cr)
13538.50
Glaxosmithkline Phar (BSE)
 2132.75 (3.26%)
M.Cap ( in Cr)
36130.07
Shareholding Pattern More
FI/BANKS/INSURANCE 5.58 %
PROMOTERS 49.71 %
MUTUAL FUNDS/UTI 4.08 %
NON-INSTITUTION 24.46 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS More
F & O Quotes